Pfizer reports positive Phase III results for haemophilia B treatment BeneFIX

Pfizer has reported positive results from its Phase III trial comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe haemophilia B.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news